Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
AstraZeneca
Harvard Business School
McKesson
Medtronic

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR VESICARE LS


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Vesicare Ls

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00333112 ↗ A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. Completed Astellas Pharma Inc Phase 4 2006-05-01 A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.
NCT00368706 ↗ A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients Completed Astellas Pharma Inc Phase 3 2006-09-01 To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid
NCT00431041 ↗ Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) Completed Astellas Pharma Canada, Inc. Phase 4 2006-12-01 The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
NCT00431041 ↗ Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) Completed Astellas Pharma Inc Phase 4 2006-12-01 The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vesicare Ls

Condition Name

Condition Name for Vesicare Ls
Intervention Trials
Overactive Bladder 24
Urinary Bladder, Overactive 15
Urinary Incontinence 6
Urologic Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vesicare Ls
Intervention Trials
Urinary Bladder, Overactive 45
Urinary Incontinence 10
Enuresis 10
Urinary Bladder Diseases 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vesicare Ls

Trials by Country

Trials by Country for Vesicare Ls
Location Trials
United States 330
Canada 31
Germany 18
Hungary 15
United Kingdom 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vesicare Ls
Location Trials
California 15
Texas 13
Pennsylvania 13
Florida 13
New York 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vesicare Ls

Clinical Trial Phase

Clinical Trial Phase for Vesicare Ls
Clinical Trial Phase Trials
Phase 4 27
Phase 3 15
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vesicare Ls
Clinical Trial Phase Trials
Completed 49
Terminated 7
Unknown status 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vesicare Ls

Sponsor Name

Sponsor Name for Vesicare Ls
Sponsor Trials
Astellas Pharma Inc 25
Astellas Pharma Europe B.V. 8
Astellas Pharma Korea, Inc. 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vesicare Ls
Sponsor Trials
Industry 51
Other 48
NIH 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Dow
Moodys
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.